Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMGN
stocks logo

AMGN

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
8.86B
+5.63%
5.252
+5.68%
8.92B
+4.91%
5.367
-3.81%
9.30B
+2.34%
5.324
+0.26%
Estimates Revision
The market is revising Upward the revenue expectations for Amgen Inc. (AMGN) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by -8.55%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.13%
In Past 3 Month
Stock Price
Go Down
down Image
-8.55%
In Past 3 Month
22 Analyst Rating
up Image0
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 325.00 USD with a low forecast of 252.00 USD and a high forecast of 400.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
10 Hold
1 Sell
Moderate Buy
up Image0
Current: 290.050
sliders
Low
252.00
Averages
325.00
High
400.00
up Image0
Current: 290.050
sliders
Low
252.00
Averages
325.00
High
400.00
Guggenheim
Vamil Divan
Neutral
initiated
$288
2025-05-20
Reason
Guggenheim
Vamil Divan
Price Target
$288
2025-05-20
initiated
Neutral
Reason
Guggenheim analyst Vamil Divan assumed coverage of Amgen with a Neutral rating and $288 price target. With the pending loss of U.S. market exclusivity for both Prolia and Xgeva later this month and the expected upcoming erosion for blockbuster medications such as Enbrel and Otezla, the firm views Amgen as a company with a portfolio that is "in transition," but with "an intriguing pipeline of assets that could help to replace sales that are at risk," the analyst tells investors.
Piper Sandler
Overweight
downgrade
$329 -> $328
2025-05-16
Reason
Piper Sandler
Price Target
$329 -> $328
2025-05-16
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Amgen to $328 from $329 and keeps an Overweight rating on the shares. The firm notes that monthly third-party prescription data for April 2025 are now available. The volume growth trajectory for Repatha and Tezspire remains aggressive, and these dynamics are key components of Piper's constructive thesis on the shares.
Erste Group
Hans Engel
Buy
to
Hold
downgrade
2025-05-08
Reason
Erste Group
Hans Engel
Price Target
2025-05-08
downgrade
Buy
to
Hold
Reason
Erste Group analyst Hans Engel downgraded Amgen to Hold from Buy. The company's planned weight loss products are still in the clinical trial phase and are only likely to make moderate contributions to sales growth in the coming years, the analyst tells investors in a research note.
UBS
Colin Bristow
Hold
Maintains
$315 → $319
2025-04-14
Reason
UBS
Colin Bristow
Price Target
$315 → $319
2025-04-14
Maintains
Hold
Reason
Morgan Stanley
Terence Flynn
Hold
Maintains
$328 → $330
2025-04-09
Reason
Morgan Stanley
Terence Flynn
Price Target
$328 → $330
2025-04-09
Maintains
Hold
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Amgen to $330 from $328 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
B of A Securities
Tim Anderson
Sell
Maintains
$275 → $294
2025-03-05
Reason
B of A Securities
Tim Anderson
Price Target
$275 → $294
2025-03-05
Maintains
Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amgen Inc (AMGN.O) is 14.11, compared to its 5-year average forward P/E of 14.11. For a more detailed relative valuation and DCF analysis to assess Amgen Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
14.11
Current PE
14.11
Overvalued PE
15.23
Undervalued PE
12.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
10.23
Current EV/EBITDA
11.09
Overvalued EV/EBITDA
11.15
Undervalued EV/EBITDA
9.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
4.86
Current PS
4.41
Overvalued PS
5.28
Undervalued PS
4.44

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 106.73% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

AMGN News & Events

Events Timeline

(ET)
2025-06-02
08:06:58
Amgen presents new interim results from the global Phase 3 DeLLphi-304 trial
select
2025-05-07 (ET)
2025-05-07
12:54:19
Amgen says MHRA granted marketing authorization to Tepezza for TED
select
2025-05-01 (ET)
2025-05-01
16:03:48
Amgen backs FY25 adjusted EPS view $20.00-$21.20, consensus $20.63
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
01:07 AMMarketWatch
Dow's nearly 150-point drop led by losses for Nike, Merck shares

  • Market Performance: The Dow Jones Industrial Average is down 148 points (0.3%) due to declines in shares of Nike and Merck.

  • Impacting Companies: Nike Inc. and Merck & Co. are identified as key contributors to the intraday decline of the blue-chip index.

Preview
7.0
06-17CNBC
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

  • Lawmakers Challenge Pharmaceutical Tax Practices: Democratic lawmakers, including Sen. Elizabeth Warren and Rep. Jan Schakowsky, are questioning major pharmaceutical companies about their low federal tax payments despite high profits, alleging they exploit offshore tax loopholes created by the 2017 Tax Cuts and Jobs Act.

  • Impact of Proposed Legislation: The ongoing multitrillion-dollar tax and spending package could solidify these tax breaks for drug companies while also proposing cuts to programs for low-income Americans, prompting concerns from Democrats about the fairness of expanding tax benefits for profitable corporations.

Preview
2.0
06-17NASDAQ.COM
Noteworthy ETF Outflows: TQQQ, AMGN, GILD, CMCSA

  • TQQQ Share Price Analysis: TQQQ's current share price is $75.01, with a 52-week low of $35 and a high of $93.7892; the comparison to the 200-day moving average can provide additional insights for investors.

  • Understanding ETFs: Exchange-traded funds (ETFs) function like stocks but involve trading "units" that can be created or destroyed based on investor demand, impacting the underlying assets held within the ETF.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amgen Inc (AMGN) stock price today?

The current price of AMGN is 290.05 USD — it has decreased -1.86 % in the last trading day.

arrow icon

What is Amgen Inc (AMGN)'s business?

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

arrow icon

What is the price predicton of AMGN Stock?

Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 325.00 USD with a low forecast of 252.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amgen Inc (AMGN)'s revenue for the last quarter?

Amgen Inc revenue for the last quarter amounts to 8.15B USD, increased 9.43 % YoY.

arrow icon

What is Amgen Inc (AMGN)'s earnings per share (EPS) for the last quarter?

Amgen Inc. EPS for the last quarter amounts to 3.20 USD, decreased -1623.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Amgen Inc (AMGN)'s fundamentals?

The market is revising Upward the revenue expectations for Amgen Inc. (AMGN) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by -8.55%.
arrow icon

How many employees does Amgen Inc (AMGN). have?

Amgen Inc (AMGN) has 28000 emplpoyees as of June 18 2025.

arrow icon

What is Amgen Inc (AMGN) market cap?

Today AMGN has the market capitalization of 155.96B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free